基于特定免疫介质的系统性红斑狼疮发作风险指数
研究利用46例即将临床发作(发作前)与53例同期无发作(非发作前)的系统性红斑狼疮患者血浆样本,检测37种免疫介质,通过随机森林和逻辑回归筛选出11种介质构建新型发作风险指数,决策曲线分析定义低、中、高评分后其最大敏感度为97%、最大特异度为98%。
要点
- 发作前与非发作前在人口学、自身抗体特异性、hSLEDAI评分、临床特征及用药上无差异。
- 37种血浆介质经变量重要性排序后筛选出17种候选介质,最终11种组合最佳反映新型发作风险指数。
- 应用决策曲线分析定义低、中、高发作风险指数评分后,该指数最大敏感度97%、最大特异度98%。
核心结论
- 研究验证了与即将临床发作相关的免疫介质改变,其中一部分介质改进了发作风险指数以识别有即将发作风险的SLE患者。
- 这种基于分子信息的主动管理方法可能对前瞻性临床试验和狼疮临床管理至关重要。
研究设计与样本
- 利用一个独特的纵向队列,从106例分类SLE患者(符合美国风湿病学会1997年修订的SLE分类标准或系统性狼疮国际协作组2012年修订的SLE分类标准)中选取样本。
- 采用微流控免疫分析检测37种SLE相关血浆介质,样本包括SLE患者即将临床发作前的46份样本(发作前)和同期无发作的53份样本(非发作前)。
- 比较发作前(发作前平均±标准差111±47天)与非发作前(非发作前99±21天)时间点的自身抗体特异性、混合SLE疾病活动指数(hSLEDAI)评分、临床特征和药物使用。
- 通过随机森林分析确定变量重要性,随后应用逻辑回归确定告知改进型发作风险指数的最佳分析物数量和类型。
主要发现
- 发作前与非发作前之间的差异与人口学、自身抗体特异性、hSLEDAI评分、临床特征及药物使用无关。
- 按变量重要性排序后,通过前向选择和后向消除得到17种血浆介质候选物,可区分发作前与非发作前访视。
- 最终11种介质的组合最佳地告知了新改进的发作风险指数,在应用决策曲线分析定义低、中、高发作风险指数评分后,该指数达到最大敏感度97%和最大特异度98%。
关键数值与推荐
- 最终11种介质组合构建的改进型发作风险指数,在决策曲线分析定义低、中、高评分后,最大敏感度为97%,最大特异度为98%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic lupus erythematosus (SLE) is marked by immune dysregulation linked to varied clinical disease activity. Using a unique longitudinal cohort of SLE patients, this study sought to identify optimal immune mediators informing an empirically refined flare risk index (FRI) reflecting altered immunity prior to clinical disease flare. METHODS: Thirty-seven SLE-associated plasma mediators were evaluated by microfluidic immunoassay in 46 samples obtained in SLE patients with an imminent clinical disease flare (preflare) and 53 samples obtained in SLE patients without a flare over a corresponding period (pre-nonflare). SLE patients were selected from a unique longitudinal cohort of 106 patients with classified SLE (meeting the American College of Rheumatology 1997 revised criteria for SLE or the Systemic Lupus International Collaborating Clinics 2012 revised criteria for SLE). Autoantibody specificities, hybrid SLE Disease Activity Index (hSLEDAI) scores, clinical features, and medication usage were also compared at preflare (mean ± SD 111 ± 47 days prior to flare) versus pre-nonflare (99 ± 21 days prior to nonflare) time points. Variable importance was determined by random forest analysis with logistic regression subsequently applied to determine the optimal number and type of analytes informing a refined FRI. RESULTS: Preflare versus pre-nonflare differences were not associated with demographics, autoantibody specificities, hSLEDAI scores, clinical features, nor medication usage. Forward selection and backward elimination of mediators ranked by variable importance resulted in 17 plasma mediator candidates differentiating preflare from pre-nonflare visits. A final combination of 11 mediators best informed a newly refined FRI, which achieved a maximum sensitivity of 97% and maximum specificity of 98% after applying decision curve analysis to define low, medium, and high FRI scores. CONCLUSION: We verified altered immune mediators associated with imminent disease flare, and a subset of these mediators improved the FRI to identify SLE patients at risk of imminent flare. This molecularly informed, proactive management approach could be critical in prospective clinical trials and the clinical management of lupus.
引用
- Munroe ME, Blankenship D, DeFreese D, et al. A Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2023. PMID: 36245261. doi:10.1002/art.42389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。